BR0009549A - Uso das arilalcanoil piridazinas - Google Patents

Uso das arilalcanoil piridazinas

Info

Publication number
BR0009549A
BR0009549A BR0009549-4A BR0009549A BR0009549A BR 0009549 A BR0009549 A BR 0009549A BR 0009549 A BR0009549 A BR 0009549A BR 0009549 A BR0009549 A BR 0009549A
Authority
BR
Brazil
Prior art keywords
pyridazines
arylalkanoyl
arylalcanoil
osteoporosis
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0009549-4A
Other languages
English (en)
Inventor
Jonas Rochus
Michael Wolf
Norbert Beier
Franz-Werner Kluxen
Claus Fittschen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of BR0009549A publication Critical patent/BR0009549A/pt
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: "USO DAS ARILALCANOIL PIRIDAZINAS". O uso dos compostos da fórmula 1 na qual R^ 1^, R^ 2^, Q e B são como definidos na reivindicação I e/ou os sais fisiologicamente aceitáveis dos mesmos para a preparação de um medicamento para o tratamento de osteoporose, tumores, ateroesclero-se, artrite reumatóide, esclerose múltipla, diabetes mellitus, colite ulcerativa e AIDS.
BR0009549-4A 1999-04-06 2000-03-15 Uso das arilalcanoil piridazinas Pending BR0009549A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19915364A DE19915364A1 (de) 1999-04-06 1999-04-06 Verwendung von Arylalkanoylpyridazinen
PCT/EP2000/002280 WO2000059484A2 (de) 1999-04-06 2000-03-15 Verwendung von arylalkanoylpyridazinen

Publications (1)

Publication Number Publication Date
BR0009549A true BR0009549A (pt) 2002-03-26

Family

ID=7903583

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009549-4A Pending BR0009549A (pt) 1999-04-06 2000-03-15 Uso das arilalcanoil piridazinas

Country Status (18)

Country Link
EP (1) EP1143944A3 (pt)
JP (1) JP2002541095A (pt)
KR (1) KR20020000550A (pt)
CN (1) CN1355702A (pt)
AR (1) AR023261A1 (pt)
AU (1) AU3811600A (pt)
BR (1) BR0009549A (pt)
CA (1) CA2367051A1 (pt)
CZ (1) CZ20013598A3 (pt)
DE (1) DE19915364A1 (pt)
HU (1) HUP0200311A3 (pt)
ID (1) ID30381A (pt)
MX (1) MXPA01010034A (pt)
NO (1) NO20014845L (pt)
PL (1) PL350963A1 (pt)
RU (1) RU2001129703A (pt)
WO (1) WO2000059484A2 (pt)
ZA (1) ZA200109120B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040087335A (ko) 2002-03-01 2004-10-13 야마노우치세이야쿠 가부시키가이샤 질소 함유 복소환 화합물
DE10224888A1 (de) * 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
DE10225574A1 (de) * 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
WO2005002590A1 (ja) * 2003-07-01 2005-01-13 Astellas Pharma Inc. 骨量増加誘導剤
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632549A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
DE19915365A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazin-Derivate

Also Published As

Publication number Publication date
NO20014845D0 (no) 2001-10-05
DE19915364A1 (de) 2000-10-12
CA2367051A1 (en) 2000-10-12
ID30381A (id) 2001-11-29
HUP0200311A2 (hu) 2002-11-28
WO2000059484A2 (de) 2000-10-12
CN1355702A (zh) 2002-06-26
ZA200109120B (en) 2003-11-13
EP1143944A2 (de) 2001-10-17
MXPA01010034A (es) 2002-04-24
JP2002541095A (ja) 2002-12-03
RU2001129703A (ru) 2004-02-20
HUP0200311A3 (en) 2002-12-28
AU3811600A (en) 2000-10-23
AR023261A1 (es) 2002-09-04
CZ20013598A3 (cs) 2002-01-16
EP1143944A3 (de) 2002-09-11
NO20014845L (no) 2001-10-05
PL350963A1 (en) 2003-02-24
KR20020000550A (ko) 2002-01-05
WO2000059484A3 (de) 2001-08-23

Similar Documents

Publication Publication Date Title
MY146279A (en) Compounds affecting glucokinase
BR9713704A (pt) Ceto-benzamida, uso da mesma, e, preparação de droga
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
SE9903544D0 (sv) Novel compounds
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
IL145068A0 (en) The use of glycine betaine to prepare a pharmaceutical composition
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
SE0001899D0 (sv) New compounds
BR9917007A (pt) Moduladores de ccr5
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
SE9802729D0 (sv) Novel Compounds
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
BR0113590A (pt) 7-oxo-piridopirimidinas
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR0009549A (pt) Uso das arilalcanoil piridazinas
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
SE0102057D0 (sv) New Salts I
BR9911679A (pt) Sais de paroxetina

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]